Last Updated: November 16, 2026

SYLVANT Drug Profile

« Back to Dashboard


Summary for Tradename: SYLVANT
High Confidence Patents:8
Applicants:2
BLAs:1
Recent Clinical Trials: See clinical trials for SYLVANT
Recent Clinical Trials for SYLVANT

Identify potential brand extensions & biosimilar entrants

SponsorPhase
United States Department of DefensePhase 2
Recordati Rare DiseasesPhase 2
Massachusetts General HospitalPhase 2

See all SYLVANT clinical trials

Pharmacology for SYLVANT
Mechanism of ActionInterleukin-6 Antagonists
Established Pharmacologic ClassInterleukin-6 Antagonist
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SYLVANT Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SYLVANT Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 7,670,597 2026-08-15 DrugPatentWatch analysis and company disclosures
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 7,731,959 2022-03-22 DrugPatentWatch analysis and company disclosures
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 8,603,480 2029-07-15 DrugPatentWatch analysis and company disclosures
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 8,771,699 2029-01-09 DrugPatentWatch analysis and company disclosures
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 8,790,656 2026-06-08 DrugPatentWatch analysis and company disclosures
Recordati Rare Diseases, Inc. SYLVANT siltuximab For Injection 125496 9,089,578 2033-04-25 DrugPatentWatch analysis and company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for SYLVANT Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for SYLVANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2014/048 Ireland ⤷  Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140522
92543 Luxembourg ⤷  Start Trial PRODUCT NAME: SILTUXIMAB
5022-2014 Slovakia ⤷  Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928 20140522
300687 Netherlands ⤷  Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928/001-002 20140527
CA 2014 00047 Denmark ⤷  Start Trial PRODUCT NAME: SILTUXIMAB; REG. NO/DATE: EU/1/14/928/001-002 20140522
51/2014 Austria ⤷  Start Trial PRODUCT NAME: SILTUXIMAB; REGISTRATION NO/DATE: EU/1/14/928 20140522
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

SYLVANT Market Dynamics, Patent Exclusivity, and Financial Trajectory

Last updated: November 3, 2026

SYLVANT, or siltuximab, is a narrow-market biologic approved by the FDA for adults with human immunodeficiency virus-negative and human herpesvirus-8-negative multicentric Castleman disease, or MCD. Its commercial profile is shaped by a very small eligible population, high clinical value in a life-threatening disease, intravenous administration, and limited direct competition. Johnson & Johnson does not report SYLVANT revenue separately, so product-level sales, margins, and growth rates cannot be calculated from public company filings.

What is SYLVANT and which patients can receive it?

SYLVANT is a chimeric monoclonal antibody that binds interleukin-6, or IL-6. The FDA approved it on April 23, 2014, under the orphan-drug framework for adults with HIV-negative and HHV-8-negative MCD who do not have a satisfactory treatment option [1].

The labeled regimen is 11 mg/kg administered by intravenous infusion over one hour every three weeks until treatment failure or unacceptable toxicity [2].

Attribute SYLVANT data
Active ingredient Siltuximab
Sponsor Janssen Biotech, a Johnson & Johnson company
Drug class Anti-IL-6 monoclonal antibody
FDA approval April 23, 2014
Initial FDA indication HIV-negative, HHV-8-negative multicentric Castleman disease
Administration Intravenous infusion
Dose 11 mg/kg every three weeks
Primary commercial market Rare hematologic and inflammatory disease
FDA pathway Biologics license application
Orphan status Yes
Orange Book listing Not applicable to biologic products
Biosimilar status No FDA-approved SYLVANT biosimilar identified in the FDA Purple Book through the available public record

SYLVANT is not approved for patients with HIV-associated or HHV-8-associated MCD. That restriction materially limits the addressable population.

How large is the SYLVANT market?

The SYLVANT market is small in patient volume but high in treatment intensity. MCD is a rare lymphoproliferative disorder with heterogeneous presentation, limited epidemiologic data, and underdiagnosis risk. The drug’s commercial market is narrower than the broader IL-6 inhibitor category because its label is restricted to a specific MCD population.

Demand is driven by four factors:

  1. Confirmation of HIV-negative and HHV-8-negative disease.
  2. Recognition of idiopathic or HHV-8-negative MCD by hematologists.
  3. Access to specialty infusion centers.
  4. Reimbursement for long-term intravenous treatment.

The market does not scale like a conventional oncology product. Patient growth depends primarily on diagnosis and treatment penetration rather than broad disease prevalence. The small population limits volume-based revenue expansion, while chronic repeat dosing creates recurring revenue from each treated patient.

What are the main commercial demand drivers?

SYLVANT has several demand advantages:

  • It is specifically approved for idiopathic multicentric Castleman disease.
  • The pivotal randomized study showed improvement in durable tumor and symptomatic response compared with placebo plus best supportive care [3].
  • It addresses a serious disease with limited approved treatment options.
  • The every-three-week schedule supports chronic maintenance treatment.
  • Its mechanism directly targets IL-6, a central mediator of systemic inflammatory symptoms.

The commercial constraints are equally important:

  • MCD is difficult to diagnose and classify.
  • Treatment is intravenous rather than oral or subcutaneous.
  • The eligible population excludes HIV-positive and HHV-8-positive patients.
  • Long-term outcomes are based on a limited rare-disease evidence base.
  • Physician treatment patterns vary, particularly after failure or intolerance.
  • Competing off-label therapies are available.

What is the financial trajectory of SYLVANT?

Johnson & Johnson does not disclose SYLVANT net sales as a standalone line item in its annual reports. The product is commercially immaterial relative to the company’s largest pharmaceutical franchises, including DARZALEX, STELARA, TREMFYA, ERLEADA, and other specialty medicines [4].

No reliable public data establish:

  • Annual SYLVANT revenue.
  • Quarterly sales growth.
  • Product gross margin.
  • Regional sales mix.
  • Patient starts or treated-patient counts.
  • Net price after rebates and discounts.
  • Revenue contribution by MCD subtype.

The most defensible financial assessment is that SYLVANT is a small, recurring-revenue orphan biologic rather than a major growth asset. Its financial trajectory likely depends on stable treatment of a limited patient pool, pricing and reimbursement, and gradual diagnostic expansion. Large revenue acceleration would require either a new approved indication or meaningful expansion of the diagnosed and treated MCD population.

Financial metric Public disclosure
Standalone annual revenue Not separately disclosed
Standalone quarterly revenue Not separately disclosed
Reported product margin Not separately disclosed
Revenue guidance Not separately disclosed
Patient volume Not separately disclosed
Geographic sales Not separately disclosed
Product-specific R&D spending Not separately disclosed
Product-specific acquisition value Not publicly identified as a standalone transaction

How does SYLVANT compare with competing treatments?

SYLVANT competes with both approved and off-label therapies. Its most important competitive threat is not another FDA-approved product with the same narrow label. The main alternatives are IL-6 receptor blockade, B-cell depletion, corticosteroids, cytotoxic chemotherapy, and other immunomodulatory approaches.

Treatment Role in MCD Commercial impact on SYLVANT
SYLVANT FDA-approved for HIV-negative, HHV-8-negative MCD Reference treatment for labeled population
Tocilizumab IL-6 receptor inhibitor; approved in other diseases and used off-label in MCD Mechanistic alternative, particularly where access or physician preference favors it
Rituximab Commonly used in HHV-8-associated disease and selected other settings Strong off-label competitor
Corticosteroids Symptom control and combination therapy Low-cost treatment that may delay biologic initiation
Chemotherapy Used in refractory or aggressive disease Rescue alternative
Thalidomide, lenalidomide, or other agents Selected refractory cases Limited but relevant off-label competition
Supportive care Used alongside disease-directed therapy Does not replace SYLVANT in patients requiring IL-6 blockade

Tocilizumab is the closest mechanistic competitor, but it is not an interchangeable biosimilar or generic substitute for SYLVANT. It targets the IL-6 receptor, while siltuximab binds IL-6 itself. Clinical selection depends on disease subtype, prior treatment, physician experience, payer policy, and the patient’s response.

What patents protect SYLVANT?

SYLVANT is a biologic, so its exclusivity profile differs from that of a conventional small-molecule drug. The FDA Orange Book generally does not list biologic product patents in the same manner as small-molecule drug patents. Patent disputes involving a biologic reference product are handled under the Biologics Price Competition and Innovation Act, or BPCIA, rather than through the standard Orange Book Paragraph IV process.

The relevant protection layers include:

  • Composition-of-matter or antibody claims.
  • Binding-site and epitope claims.
  • Use claims covering treatment of MCD or IL-6-mediated disorders.
  • Cell-line and production claims.
  • Manufacturing and purification claims.
  • Formulation and stability claims.
  • Regulatory exclusivity under the BPCIA.

The FDA approved SYLVANT in 2014. For a reference biologic first licensed after March 23, 2010, the BPCIA provides 12 years of reference-product exclusivity, subject to statutory rules governing the calculation of the period. On that basis, the core U.S. regulatory exclusivity period would extend into 2026. Patent protection can extend beyond regulatory exclusivity, but the exact commercial barrier depends on the claims that remain unexpired and enforceable.

A definitive SYLVANT patent-expiration date cannot be reduced to a single public date because biologic estates can include multiple patents with different filing dates, continuation practice, terminal disclaimers, patent-term adjustments, and jurisdiction-specific outcomes.

Are SYLVANT patents listed in the Orange Book?

No. SYLVANT is licensed as a biologic, and biologic patent information is not ordinarily presented through the Orange Book framework used for approved small-molecule drugs. The FDA Purple Book identifies licensed biological products and biosimilar or interchangeable relationships, but it is not a complete patent-expiration database [5].

When does SYLVANT lose exclusivity?

The key U.S. regulatory milestone is the end of the 12-year reference-product exclusivity period, which falls in or around 2026 based on the 2014 initial licensure date. That date does not automatically create immediate biosimilar competition.

A biosimilar applicant must satisfy FDA requirements for biosimilarity and comply with BPCIA notice and litigation procedures. Patent litigation can delay launch even after regulatory exclusivity expires. Commercial entry also depends on:

  • Whether a biosimilar developer has invested in a very small market.
  • Whether the reference sponsor asserts manufacturing or formulation patents.
  • Whether the applicant receives an interchangeable designation.
  • Whether the commercial opportunity supports clinical-development and manufacturing costs.
  • Whether payers prefer a lower-cost alternative.

For a rare-disease biologic with a small treated population, the economic incentive for biosimilar entry is weaker than for high-volume products such as adalimumab, ustekinumab, or trastuzumab.

Are there Paragraph IV challenges to SYLVANT?

The standard Paragraph IV certification process applies to patents listed in the Orange Book for small-molecule products. It is not the normal pathway for challenging SYLVANT exclusivity.

A potential competitor would generally pursue the biosimilar pathway under the BPCIA. Public sources do not identify a major SYLVANT biosimilar litigation campaign, settlement agreement, or announced commercial biosimilar launch. The absence of a public challenge is consistent with the product’s small addressable market, although it does not eliminate future entry risk.

What is the FDA regulatory status of SYLVANT?

SYLVANT remains an FDA-approved biologic for its original MCD indication. It is not a broad inflammatory-disease IL-6 product. The label requires confirmation of the relevant disease subtype and excludes patients with HIV-associated or HHV-8-associated MCD.

The clinical evidence supporting approval came from a randomized study in which durable tumor and symptomatic response was higher in the siltuximab arm than in the placebo arm [3]. The evidence is commercially useful because it supports disease-directed treatment rather than purely symptomatic management, but its narrow indication limits expansion into larger markets.

What manufacturing and intellectual-property barriers protect SYLVANT?

Manufacturing creates a meaningful barrier even if composition patents expire. A biosimilar developer would need to establish:

  • A comparable antibody structure and function.
  • Consistent cell-culture performance.
  • Process control across commercial batches.
  • Comparable impurity and aggregate profiles.
  • Validated analytical methods.
  • A compliant sterile injectable manufacturing process.
  • Sufficient clinical and pharmacokinetic evidence for FDA review.

SYLVANT’s intravenous formulation and low-volume orphan market raise the cost-per-patient of commercial entry. A biosimilar company would also face limited manufacturing scale and uncertain payer uptake. These factors can preserve practical market protection beyond the formal patent term.

What licensing deals involve SYLVANT?

SYLVANT is associated with Janssen Biotech and Johnson & Johnson. Public company disclosures do not identify a major external licensing transaction that independently reports SYLVANT economics, such as an upfront payment, royalty rate, or territory-specific commercialization right.

The product originated within the Centocor/Janssen research organization under the development code CNTO 328. No publicly disclosed licensing structure provides a basis for assigning separate royalty obligations or calculating product-level net economics.

What generic or biosimilar launch risks exist?

Near-term conventional generic risk is effectively absent because SYLVANT is a biologic. The relevant risk is biosimilar entry.

Risk factor Assessment
Small-molecule generic substitution Not applicable
Biosimilar development Technically possible
Automatic pharmacy substitution Unlikely without interchangeability and payer support
Patent litigation risk Possible after or around regulatory exclusivity expiry
Commercial launch incentive Limited by rare-disease volume
Price erosion risk Moderate if one biosimilar launches; lower if entry remains limited
Volume erosion risk Dependent on payer preference and physician confidence
Off-label substitution Existing risk from tocilizumab and other therapies

The most likely initial post-exclusivity scenario is limited biosimilar entry with gradual payer-driven substitution rather than rapid replacement. A single approved biosimilar could pressure net price, but the product’s small volume may limit the absolute revenue impact.

How strong is the SYLVANT patent estate?

The SYLVANT patent estate is commercially meaningful but difficult to assess from public regulatory sources alone. The strongest practical protections are likely the combination of biologic manufacturing complexity, regulatory exclusivity, specialized clinical positioning, and physician familiarity.

Patent strength should be evaluated across four questions:

  1. Whether core antibody claims remain enforceable.
  2. Whether method-of-use claims cover the commercially relevant MCD population.
  3. Whether formulation or manufacturing claims can delay biosimilar launch.
  4. Whether potential damages justify litigation in a small market.

The estate may be strategically stronger than its revenue profile suggests, but its economic value is constrained by the limited number of treatable patients.

What is the outlook for SYLVANT revenue?

The base-case outlook is stable to modestly declining revenue after regulatory exclusivity begins to lapse, absent a new indication or meaningful expansion in diagnosis. The product can retain recurring revenue because MCD treatment may continue over extended periods, but the patient pool is too small to support typical blockbuster growth.

Potential upside factors include:

  • Higher diagnosis rates for idiopathic MCD.
  • Earlier use in treatment algorithms.
  • Greater hematologist awareness.
  • Expanded reimbursement.
  • New data supporting additional IL-6-mediated diseases.
  • A new formulation that reduces infusion burden.

Potential downside factors include:

  • Biosimilar entry.
  • Off-label use of lower-cost IL-6 therapies.
  • Reimbursement restrictions.
  • Treatment discontinuation after response or toxicity.
  • Diagnostic substitution into other disease categories.
  • A shrinking commercial field force for a low-revenue product.

Key Takeaways

  • SYLVANT is a niche orphan biologic for HIV-negative, HHV-8-negative multicentric Castleman disease.
  • FDA approval occurred in 2014, and BPCIA reference-product exclusivity extends into approximately 2026.
  • SYLVANT is not an Orange Book product; biosimilar competition is governed by the BPCIA and tracked through the Purple Book framework.
  • Johnson & Johnson does not separately disclose SYLVANT revenue, so no verified product-level sales trend or financial CAGR is available.
  • The main competitive threats are off-label tocilizumab, rituximab, corticosteroids, chemotherapy, and future biosimilars.
  • The rare-disease population limits revenue growth but also reduces the incentive for aggressive biosimilar development.
  • Manufacturing complexity, clinical specialization, and reimbursement access provide practical protection beyond formal patent expiry.
  • The most probable commercial trajectory is recurring but modest revenue, followed by gradual price pressure if a biosimilar enters.

FAQs About SYLVANT Market and Exclusivity

Is SYLVANT a blockbuster drug?

No. Johnson & Johnson has not reported SYLVANT as a standalone blockbuster product, and the eligible MCD population is too small to support the sales scale associated with major oncology or immunology franchises.

Can patients receive SYLVANT for HIV-associated Castleman disease?

No. The FDA label is limited to adults with HIV-negative and HHV-8-negative MCD. HIV-associated and HHV-8-associated disease falls outside the approved indication.

Is there a generic version of SYLVANT?

No conventional generic can substitute for SYLVANT. Any competing product would need to be developed as a biosimilar or as a separate biologic.

Does SYLVANT have a biosimilar competitor?

No FDA-approved SYLVANT biosimilar is identified in the available public record. Future biosimilar entry remains possible after the reference-product exclusivity period and any enforceable patent barriers.

What is the biggest long-term risk to SYLVANT sales?

The largest risk is a combination of limited market size, off-label use of competing IL-6 therapies, and biosimilar price competition after regulatory exclusivity expires.

References

  1. U.S. Food and Drug Administration. (2014). FDA approves Sylvant to treat multicentric Castleman disease. https://www.fda.gov
  2. U.S. Food and Drug Administration. (2023). Sylvant (siltuximab) prescribing information. Janssen Biotech, Inc.
  3. van Rhee, F., Wong, R. S. M., Munshi, N., Rossi, J. F., Ke, X., Fosså, A., et al. (2014). Siltuximab for multicentric Castleman’s disease: A randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 15(9), 966-974.
  4. Johnson & Johnson. (2024). Annual report and Form 10-K.
  5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.